NCT00557232View on ClinicalTrials.gov

Intraocular Bevacizumab (Avastin) for Rubeosis Iridis

PHASE4CompletedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

October 31, 2011

Study Completion Date

November 30, 2011

Conditions

GlaucomaRubeosis Iridis

Interventions

DRUG

bevacizumab

1.25mg/month

All Listed Sponsors

lead

Instituto de Olhos de Goiania

OTHER

NCT00557232 - Intraocular Bevacizumab (Avastin) for Rubeosis Iridis | Biotech Hunter | Biotech Hunter